CA Patent

CA3038500A1 — Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Assigned to US Department of Health and Human Services · Expires 2018-04-05 · 8y expired

What this patent protects

The present disclosure relates to a method of treating urothelial carcinoma using Cabozantinib, a kinase inhibitor.

USPTO Abstract

The present disclosure relates to a method of treating urothelial carcinoma using Cabozantinib, a kinase inhibitor.

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: CA3038500A1
Jurisdiction: CA
Classification: —
Expires: 2018-04-05
Drug substance claim: No
Drug product claim: No
Assignee: US Department of Health and Human Services
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.